Gene therapy shows promise for future treatment of addiction in humans, a new study reports. Read More
Advertisements
Microdosing, a growing trend where people take small doses for psychedelic drugs, is associated with improved mood, focus, and creativity. For some, microdosing may provide a possible alternative to SSRI antidepressants. However, researchers warn of some potential problems with microdosing, including negative side effects, psychological stigma, and exposure to elicit, black market products. Read More
Metformin, a common diabetes medication, shows promise for the treatment of anxiety and depression. Read More
Anti-inflammatory medications, such as those commonly prescribed for arthritis, improve depressive symptoms in those with MDD. Read More
Researchers report diet and weight may hinder the response to medications for some with bipolar disorder. The study found those who had a better quality of diet and lower BMI responded better to treatments than those who were overweight and ate foods that promoted inflammation. Read More
A new study reports people with Alzheimer's disease are more likely to use antipsychotic medications, and for longer periods of time, than the general public. Read More
Two new studies consider the potential of using psychedelics to help treat depression. Imperial College London researchers report psilocybin, the active compound in magic mushrooms, can help to relieve symptoms of depression without the dulling of emotions associated with SSRIs. The researchers note the psychedelic experience could help to maintain long term mental health for those with treatment resistant depression. Read More
Researchers report ketamine's antidepressive effects require activation of opioid receptors in the brain. The study highlights the interaction between depression, pain and opioid addiction. Read More
A single dose of the psychedelic psilocybin reduces depression, anxiety, and feelings of hopelessness in cancer patients for 12 months after the drug is administered. Read More
Brain connections strengthened with treatment from fast-acting antidepressants, such as ketamine, are consolidated during deep sleep. Researchers propose rapid antidepressant treatments share the ability to regulate both synaptic potentiation and homeostatic mechanisms, which may contribute to how the brain reorganizes its activity to defeat depression. Read More
A new study implicates serotonin 2c receptors with metabolic side effects caused by a common class of antipsychotic medications. Read More
In a new study, researchers report on the potential for using psilocybin, a hallucinogenic compound derived from magic mushrooms, for treating patients with treatment resistant depression. Read More
